Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study
has two parts:
Part A - first in human study in which patients receive a single dose of ANK-700 Part B -
patients will receive three doses of either ANK-700 or placebo